FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2023363152> ?p ?o ?g. }

• W2023363152 endingPage "P06.106" @default.
• W2023363152 startingPage "P06.106" @default.
• W2023363152 abstract "Objective: We assessed rates of withdrawal-related events following abrupt discontinuation and gradual tapering of clobazam during Phase I–III studies. Background Clobazam, a 1,5-benzodiazepine, is under FDA review for LGS. Design/Methods: Potential withdrawal-related AEs following abrupt CLB discontinuation were assessed in 4 multiple-dosage Phase I trials (dosing 8−34 days). These studies employed therapeutic (20 and 40 mg/day) and supratherapeutic dosages (120 and 160 mg/day). These events were also assessed in Phase II/III studies (dosing ≤18 weeks) and their open-label extension (OLE) (≤5 years). In these studies, gradual tapering over 2–3 weeks was conducted. Withdrawal-related AEs included sedation, somnolence, insomnia, irritability, anxiety, and seizures. AEs must have occurred ≥1 day following last clobazam dose and within 30 days after last dose, or must have been deemed withdrawal symptoms by investigators. Results: Phase I participants received steady-state dosages of 20–160 mg/day, with the vast majority receiving ≥40 mg/day and ∼50% receiving ≥120 mg/day (≤4-times maximum daily dosage in Phase II/III). In contrast, LGS patients received ≤40 mg/day during Phase II/III and ≤80 mg/day in the OLE. 87 patients discontinued clobazam during Phase II/III and tapered drug. None reported withdrawal-related AEs. Abrupt discontinuation led to AEs consistent with withdrawal. 93 AEs were reported for 68 of 207 in Phase I studies. Nearly all AEs occurred after abrupt discontinuation of clobazam ≥40 mg/day, with ∼50% occurring at ≥120 mg/day. The majority of AEs following abrupt discontinuation were mild, and included headache, insomnia, anxiety, and tremor. No status epilepticus occurred during withdrawal/tapering. Conclusions: Withdrawal-related AEs did not occur during 2- to 3-week tapering at the conclusion of Phase II/III studies of clobazam. No withdrawal-related AEs have been observed with long-term therapy through 5 years In Phase I, abrupt withdrawal led to generally mild AEs at rates comparable to those observed for other benzodiazepines. Supported by: Lundbeck Inc. Disclosure: Dr. Tolbert has received personal compensation for activities with Lundbeck Research USA, Inc as an employee. Dr. Harris has received research support from Lundbeck Research USA, Inc. Dr. Bekersky has received personal compensation for activities with Lundbeck Research USA, Inc. as an employee. Dr. Owen has received personal compensation for activities with Lundbeck Research USA, Inc." @default.
• W2023363152 created "2016-06-24" @default.
• W2023363152 creator A5002754929 @default.
• W2023363152 creator A5019914847 @default.
• W2023363152 creator A5028202669 @default.
• W2023363152 creator A5076831680 @default.
• W2023363152 date "2012-04-22" @default.
• W2023363152 modified "2023-10-18" @default.
• W2023363152 title "Withdrawal-Related Adverse Events from Clinical Trials of Clobazam in Lennox-Gastaut Syndrome (LGS) (P06.106)" @default.
• W2023363152 doi "https://doi.org/10.1212/wnl.78.1_meetingabstracts.p06.106" @default.
• W2023363152 hasPublicationYear "2012" @default.
• W2023363152 type Work @default.
• W2023363152 sameAs 2023363152 @default.
• W2023363152 citedByCount "1" @default.
• W2023363152 countsByYear W20233631522012 @default.
• W2023363152 crossrefType "journal-article" @default.
• W2023363152 hasAuthorship W2023363152A5002754929 @default.
• W2023363152 hasAuthorship W2023363152A5019914847 @default.
• W2023363152 hasAuthorship W2023363152A5028202669 @default.
• W2023363152 hasAuthorship W2023363152A5076831680 @default.
• W2023363152 hasConcept C118552586 @default.
• W2023363152 hasConcept C126322002 @default.
• W2023363152 hasConcept C187212893 @default.
• W2023363152 hasConcept C197934379 @default.
• W2023363152 hasConcept C2777907850 @default.
• W2023363152 hasConcept C2778186239 @default.
• W2023363152 hasConcept C2779307984 @default.
• W2023363152 hasConcept C42219234 @default.
• W2023363152 hasConcept C535046627 @default.
• W2023363152 hasConcept C71924100 @default.
• W2023363152 hasConceptScore W2023363152C118552586 @default.
• W2023363152 hasConceptScore W2023363152C126322002 @default.
• W2023363152 hasConceptScore W2023363152C187212893 @default.
• W2023363152 hasConceptScore W2023363152C197934379 @default.
• W2023363152 hasConceptScore W2023363152C2777907850 @default.
• W2023363152 hasConceptScore W2023363152C2778186239 @default.
• W2023363152 hasConceptScore W2023363152C2779307984 @default.
• W2023363152 hasConceptScore W2023363152C42219234 @default.
• W2023363152 hasConceptScore W2023363152C535046627 @default.
• W2023363152 hasConceptScore W2023363152C71924100 @default.
• W2023363152 hasIssue "Meeting Abstracts 1" @default.
• W2023363152 hasLocation W20233631521 @default.
• W2023363152 hasOpenAccess W2023363152 @default.
• W2023363152 hasPrimaryLocation W20233631521 @default.
• W2023363152 hasRelatedWork W2005107590 @default.
• W2023363152 hasRelatedWork W2014212238 @default.
• W2023363152 hasRelatedWork W2080962580 @default.
• W2023363152 hasRelatedWork W2090699703 @default.
• W2023363152 hasRelatedWork W2108468621 @default.
• W2023363152 hasRelatedWork W2152598089 @default.
• W2023363152 hasRelatedWork W2396520718 @default.
• W2023363152 hasRelatedWork W2888643586 @default.
• W2023363152 hasRelatedWork W2900752836 @default.
• W2023363152 hasRelatedWork W3162698004 @default.
• W2023363152 hasVolume "78" @default.
• W2023363152 isParatext "false" @default.
• W2023363152 isRetracted "false" @default.
• W2023363152 magId "2023363152" @default.
• W2023363152 workType "article" @default.